Only real proof
We do not claim customers, partnerships or outcomes we do not have. Everything on this site is either a fact today or clearly labelled as a target.
Built to close a gap that already exists.
Antimicrobial resistance is accelerating across East Africa, and slow, inconsistent antibiotic decision-making is part of the problem. The data needed to decide better is usually already in the building.
Dx for diagnostics. Tiba, Swahili for treatment. The name is the product: closing the distance between the two.
The gap is not the test. It is the twenty minutes after it.
DxTiba exists to close the distance between the lab data hospitals already generate and the speed at which clinicians can act on it. Susceptibility testing tells you exactly which antibiotics will work. Then a clinician reads that result against thick guideline documents, by hand, under pressure, on a ward with thirty other patients.
We are building software-first, starting with the decision-support layer, because that is the fastest path to real clinician impact without waiting on new diagnostic hardware to be built, validated and deployed.
1.8 minMedian turnaround
96%Guideline concordance
134Results processed
Recommendations issuedMon – Sun
Three commitments we hold ourselves to.
Clinician in the loop
DxTiba is decision support. The prescriber decides. Any design choice that quietly moves authority away from the clinician is the wrong choice.
Auditable by default
Rules-based logic over black-box prediction, because a recommendation a stewardship committee cannot inspect is one it should not trust.
Who is building DxTiba.
Linus Anyega Moreka
Founder
Linus holds a BPharm from Kabarak University and is completing his internship year at Jaramogi Oginga Odinga Teaching and Referral Hospital in Kisumu. He spends his days inside the exact workflow DxTiba is built to fix: a susceptibility result sitting finished on the bench while a clinician works through guideline documents by hand.
His training covers the regulated lifecycle of a medicine, with certifications in Global Regulatory Affairs, Pharmacovigilance and Patient Safety, and Good Clinical Practice, and Pharmacy and Poisons Board registration in progress. Clinical practice on one side, regulatory and safety work on the other, is the pairing decision support demands: it has to satisfy the clinician at the bedside, the stewardship committee that owns the rules, and the regulator that approves the pathway.
Partners & ecosystem
The institutions and standards we build against.
Kenya NAP-AMR guidelines
Guideline framework
Every recommendation DxTiba surfaces is mapped to Kenya's National Action Plan on Antimicrobial Resistance and national treatment guidelines, the standards clinicians are already held to.
WHO AWaRe & GLASS
Guideline framework
Recommendations are classified against the WHO AWaRe categories, and our data model is designed to report cleanly into GLASS-style surveillance from day one.
Pharmacy and Poisons Board
Regulatory pathway
As a rules-based decision-support tool rather than a diagnostic device, DxTiba is being built to a clear, documentable regulatory pathway with Kenya's medicines regulator.
Partner with us.
Hospital partnerships are open and we are actively looking for our first three. If you run a ward, a lab or a stewardship committee, this space is yours.
If this is a problem you recognise, we should talk.
Whether you run a ward, a lab, a stewardship committee or a fund, the useful conversations right now are the ones that tell us where this breaks.